DOSSIER · UPDATED 18 NOV 2025

Fate Therapeutics

Fate Therapeutics, Inc. provides biotechnology services. The Company researches and develops therapies to repair and regenerate body tissues with the help of stem cells. Fate Therapeutics conducts business in the United States.

fatetherapeutics.com ↗Claim this profile

Founded: 2007
Headcount: 200
Open roles: 4
Last raised: Grant · $8M

SECTION I · THE BRIEF

Inside Fate Therapeutics

Brief #63047Updated 18 NOV 2025SAN DIEGOMEDICAL ORGANIZATIONSGRANT

Employbl Dossier

Fate Therapeutics

Founded: 2007
Headcount: 200
Open roles: 4
Last raised: Grant · $8M

Section II — RestrictedMembers only

Engineering interview process at Fate Therapeutics
Tech stack & infrastructure choices
Culture & day-to-day work style
Why join now vs. 6 months from now
Hiring focus & open headcount by team
Comp philosophy and band context

Open Fate Therapeutics brief Sign in

7-day free trial · $25/mo · cancel anytime

LEADERSHIP

Founders & key people

Randall T. Moon

Rudolf Jaenisch

Michael Rudnicki

Leonard Zon

David Scadden

Sheng Ding

Alex Rives

Phillip Beachy

OPEN ROLES

Hiring at Fate Therapeutics

Current Job Listings

Listing 0 of 4 job openings

FUNDING

Capital raised

Total Amount Raised: $1,348,828,288

Fate Therapeutics Funding Rounds

Grant
$7,900,000
Jan 30, 2025
Grant
$7,900,000
Jan 29, 2025
Grant Investors
California Institute for Regenerative Medicine (CIRM)
Post Ipo Equity
$100,000,000
Mar 19, 2024
Post Ipo Equity
$100,000,000
Mar 18, 2024
Post Ipo Equity Investors
OrbiMed Advisors
Adage Capital Management
Suvretta Capital Management
Boxer Capital
Deep Track Capital
Post Ipo Equity
$432,000,000
Jan 4, 2021
Post Ipo Equity
$432,000,000
Jan 3, 2021
Post Ipo Equity
$201,300,000
Jun 8, 2020
Post Ipo Equity
$201,300,000
Jun 7, 2020
Post Ipo Equity
$173,000,000
Sep 19, 2019
Post Ipo Equity
$173,000,000
Sep 18, 2019
Post Ipo Equity
$172,500,000
Sep 20, 2018
Post Ipo Equity
$172,500,000
Sep 19, 2018
Grant
$4,000,000
Feb 23, 2018
Grant
$4,000,000
Feb 22, 2018
Grant Investors
California Institute for Regenerative Medicine (CIRM)
Post Ipo Equity
$42,900,000
Dec 12, 2017
Post Ipo Equity
$42,900,000
Dec 11, 2017
Post Ipo Equity
$56,749,988
Dec 7, 2016
Post Ipo Equity
$56,749,988
Dec 6, 2016
Post Ipo Equity
$10,290,000
Aug 19, 2016
Post Ipo Equity
$10,290,000
Aug 18, 2016
Post Ipo Equity
$32,000,000
May 18, 2015
Post Ipo Equity
$32,000,000
May 17, 2015
Post Ipo Equity
$8,000,000
May 15, 2015
Post Ipo Equity
$8,000,000
May 14, 2015
Post Ipo Debt
$20,000,000
Jul 31, 2014
Post Ipo Debt
$20,000,000
Jul 30, 2014
Post Ipo Debt Investors
First Citizens Bank
IPO
Unknown
Jan 1, 2013
Series Unknown
$9,200,000
Aug 23, 2012
Series Unknown
$9,200,000
Aug 22, 2012
Series B
$35,988,360
May 5, 2011
Series B
$35,988,360
May 4, 2011
Series B Investors
Astellas Venture Management
OVP Venture Partners
Polaris Partners
Venrock
Arch Venture Partners
Debt Financing
$1,000,000
Apr 20, 2011
Debt Financing
$1,000,000
Apr 19, 2011
Series B
$30,000,000
Nov 16, 2009
Series B
$30,000,000
Nov 15, 2009
Series B Investors
OVP Venture Partners
Astellas Venture Management
Sanofi
Arch Venture Partners
Polaris Partners
Venrock
Series A
$12,000,000
Nov 29, 2007
Series A
$12,000,000
Nov 28, 2007
Series A Investors
Polaris Partners
Arch Venture Partners
Venrock
OVP Venture Partners